Descriptors
Classification > W - MEDICINE > WF - RESPIRATORY SYSTEM > WF 145 Respiratory System - - Therapeutics
WF 145 Respiratory System - - Therapeutics |
Documents disponibles dans cette catégorie (4)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Extend search on down-posting(s)
Home Oxygen Therapy / Alain Van Meerhaeghe / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
Home Oxygen Therapy [printed text] / Alain Van Meerhaeghe, Author ; Lieven Annemans, Author ; Patrick Haentjens, Author ; Lorena San Miguel , Author ; Bertien Buyse, Author ; Karolien Benoit, Author ; Stephan Devriese , Author ; Serge Stroobandt, Author ; Jeannine Gailly, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - XIV, 148 p. : ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 156C) .
ISSN : D/2011/10.273/25 : € 0,00
Study n° 2009-14 HTA Oxygen Therapy
Languages : English (eng)
Descriptors: Indexation
2009-14 ; Belgium ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Cystic Fibrosis ; Heart Failure ; Lung Diseases, Interstitial ; Meta-Analysis [Publication Type] ; Oxygen Inhalation Therapy ; Palliative Care ; Pulmonary Disease, Chronic Obstructive ; R156 ; Technology Assessment, Biomedical
Classification
WF 145 Respiratory System - - TherapeuticsContents note: INTRODUCTION 5 -- CHAPTER 1 DESCRIPTION OF THE BELGIAN CONTEXT 6 -- 1 INTRODUCTION 6 -- 2 METHODOLOGY 7 -- 2.1 BELGIAN PRESCRIPTION AND REIMBURSEMENT SYSTEMS 7 -- 2.1.1 Study of the two Belgian prescription systems 7 -- 2.1.2 Number of reimbursements and costs 8 -- 2.2 OXYGEN THERAPY EQUIPMENTS 8 -- 3 RESULTS 9 -- 3.1 PRESCRIPTION AND REIMBURSEMENT SYSTEMS 9 -- 3.1.1 The INAMI/RIZIV-hospital convention system 9 -- 3.1.2 Study of the RIZIV/INAMI agreement with the pharmacists 19 -- 3.1.3 Study of the main differences between both prescription channels 26 -- 3.2 OXYGEN THERAPY EQUIPMENTS 28 -- 3.2.1 Devices used in Belgium 28 -- 3.2.2 Quality control 29 -- CHAPTER 2 CLINICAL LITERATURE REVIEW 38 -- 1 INTRODUCTION 38 -- 2 METHODS 38 -- 2.1 LITERATURE SEARCH STRATEGY 38 -- 2.2 SELECTION CRITERIA 38 -- 2.3 SELECTION PROCEDURE 39 -- 2.4 CRITICAL APPRAISAL 39 -- 2.5 DATA EXTRACTION AND POOLING 40 -- 3 RESULTS 41 -- 3.1 RESEARCH AND SELECTION 41 -- 3.2 RESULTS BY INDICATION 42 -- 3.2.1 COPD 43 -- 3.2.2 Diseases requiring palliative care 57 -- 3.2.3 Heart failure 65 -- 3.2.4 Cystic fibrosis 81 -- 3.2.5 Interstitial lung disease 85 -- CHAPTER 3 ECONOMIC LITERATURE REVIEW 97 -- 1 INTRODUCTION 97 -- 2 METHODS 97 -- 2.1 LITERATURE SEARCH STRATEGY 97 -- 2.2 SELECTION PROCEDURE AND CRITERIA 97 -- 2.3 ECONOMIC EVALUATION SELECTION CRITERIA 98 -- 3 RESULTS 99 -- 3.1 STUDY DESIGN 101 -- 3.2 TYPE OF COST STUDY 101 -- 3.3 TIME FRAME OF STUDY 101 -- 3.4 PERSPECTIVE 102 -- 3.5 POPULATION 102 -- 3.6 COMPARATOR 104 -- 3.6.1 Studies comparing different interventions 104 -- 3.6.2 Studies comparing processes 104 -- 3.7 COSTS AND OUTCOMES 105 -- 3.7.1 Studies Comparing interventions 105 -- 3.7.2 Studies Comparing processes 109 -- 3.8 OTHER RELEVANT STUDIES 115 -- 3.9 MODELLING 116 -- 3.10 UNCERTAINTY ANALYSIS 117 -- 4 DISCUSSION AND CONCLUSIONS 118 -- CHAPTER 4 HEALTH ECONOMIC EVALUATION 120 -- 1 INTRODUCTION & OBJECTIVES 120 -- 2 METHODS 120 -- 2.1 MODEL 120 -- 2.2 PERSPECTIVE 121 -- 2.3 TRANSITION PROBABILITIES 121 -- 2.4 HEALTH RELATED QUALITY OF LIFE 122 -- 2.5 COSTS & RESOURCE USE 122 -- 2.5.1 Data source 122 -- 2.5.2 Analysis sample 122 -- 2.5.3 Descriptive statistics of the analysis sample 123 -- 2.5.4 Cost calculations 124 -- 2.6 ICER 125 -- 2.7 SENSITIVITY ANALYSIS 125 -- 2.8 SCENARIO ANALYSIS 125 -- 3 RESULTS 126 -- 3.1 BASE CASE SCENARIO 126 -- 3.2 ALTERNATIVE SCENARIO 126 -- 4 DISCUSSION AND CONCLUSION 128 -- CHAPTER 5 INTERNATIONAL COMPARISON 129 -- 1 INTRODUCTION 129 -- 2 METHODOLOGY 129 -- 3 RESULTS 130 -- 3.1 REGULATION OF PRESCRIPTION 130 -- 3.2 CHANNELS OF PROVISION AND HOME SUPERVISION 130 -- 3.3 REIMBURSEMENT SYSTEM 131 -- 4 DISCUSSION & CONCLUSION 135 -- CHAPTER 6 FINAL CONCLUSIONS AND LIMITATIONS 136 -- 1 CLINICAL EFFICACY 136 -- 1.1.1 COPD 136 -- 1.1.2 Patients necessitating palliative care (PC) 137 -- 1.1.3 Heart failure (HF) 137 -- 1.1.4 Cystic fibrosis (CF) 137 -- 1.1.5 Interstitial lung disease (ILD) 138 -- 2 COMPARISON OF AVAILABLE PRODUCTS 139 -- 3 COST IN BELGIUM 140 -- 4 ORGANISATION MODELS 141 -- REFERENCES 142 Link for e-copy: http://doi.org/10.57598/R156C Format of e-copy: PDF (3,7 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2577 Copies(0)
Status No copy Home Oxygen Therapy / Alain Van Meerhaeghe / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
Home Oxygen Therapy : Supplement [printed text] / Alain Van Meerhaeghe, Author ; Lieven Annemans, Author ; Patrick Haentjens, Author ; Lorena San Miguel , Author ; Bertien Buyse, Author ; Karolien Benoit, Author ; Stephan Devriese , Author ; Serge Stroobandt, Author ; Jeannine Gailly, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - 73 p. : ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 156S) .
ISSN : D/2010/10.273/25 : € 0,00
Study n° 2009-14 HTA Oxygen Therapy
Languages : English (eng)
Descriptors: Indexation
2009-14 ; Belgium ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Cystic Fibrosis ; Heart Failure ; Lung Diseases, Interstitial ; Meta-Analysis [Publication Type] ; Oxygen Inhalation Therapy ; Palliative Care ; Pulmonary Disease, Chronic Obstructive ; R156 ; Technology Assessment, Biomedical
Classification
WF 145 Respiratory System - - TherapeuticsContents note: APPENDICES OF CHAPTER 1 2 -- 1 FLOW CHART OF THE DECISION TREE IN THE RIZIV/INAMI-HOSPITAL CONVENTION2 -- 2 OVERVIEW OF THE PATHWAY ~ DISTRIBUTION AND REIMBURSEMENT FOR OXYGEN -- CONCENTRATOR WITHIN THE RIZIV/INAMI-HOSPITAL CONVENTION 5 -- 3 OVERVIEW OF THE PATHWAY ~DISTRIBUTION AND REIMBURSEMENT FOR -- SUPPLEMENTARY PORTABLE OXYGEN CYLINDERS IN ADDITION TO THE OXYGEN -- CONCENTRATOR WITHIN THE RIZIV/INAMI-HOSPITAL CONVENTION 6 -- 4 OVERVIEW OF THE PATHWAY ~ DISTRIBUTION AND REIMBURSEMENT FOR LIQUID -- OXYGEN WITHIN THE RIZIV/INAMI-HOSPITAL CONVENTION 7 -- 5 OVERVIEW OF THE PATHWAY ~ DISTRIBUTION AND REIMBURSEMENT FOR OXYGEN -- CYLINDERS WITHIN THE RIZIV/INAMIAGREEMENT WITH THE PHARMACISTS 8 -- 6 OVERVIEW OF THE PATHWAY ~ DISTRIBUTION AND REIMBURSEMENT FOR OXYGEN -- CONCENTRATOR KRÖBER BY OXYCURE WITHIN THE RIZIV/INAMI AGREEMENT -- WITH THE PHARMACISTS 9 -- 7 COMPARED PROPERTIES OF THE DIFFERENT O2 SOURCES FOR LONG-TERM OXYGEN -- THERAPY. 10 -- 8 TECHNICAL CHARACTERISTICS OF THE DIFFERENT PORTABLE CONCENTRATORS -- CURRENTLY ON THE MARKET. 11 -- APPENDICES OF CHAPTER 2 12 -- 1 SEARCH STRATEGIES 12 -- 2 CRITICAL APPRAISAL SRS - PRISMA – COPD 17 -- 3 CRITICAL APPRAISAL SRS - PRISMA – OTHER INDICATIONS 18 -- 4 CRITICAL APPRAISAL - PRIMARY STUDIES 19 -- 5 META-ANALYSIS – HEART FAILURE (HF) 21 -- 6 FUNNEL PLOTS – HEART FAILURE (HF) 25 -- APPENDICES OF CHAPTER 3 28 -- 1 SEARCH STRATEGIES 28 -- 2 DATA EXTRACTION TABLES 42 -- APPENDICES OF CHAPTER 4 71 -- 1 DATA SOURCE 71 -- 2 DEFINITION OF SELF-EMPLOYED WITHOUT MINOR RISK INSURANCE 71 -- 3 DETAILS ON COST CALCULATION 71 -- 4 DETAILS ON MORTALITY RATE IN EPSR5 72 -- 5 DETAILS ON HOSPITALISATION PROBABILITY IN EPSR5 72 -- 6 RIZIV-INAMI NOMENCLATURE CODES FOR CASE SELECTION 72 -- 7 RIZIV-INAMI CNK CODES FOR CASE SELECTION 73 Link for e-copy: http://doi.org/10.57598/R156S Format of e-copy: PDF (2,2 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2578 Copies(0)
Status No copy L’oxygénothérapie à domicile / Alain Van Meerhaeghe / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
L’oxygénothérapie à domicile [printed text] / Alain Van Meerhaeghe, Author ; Lieven Annemans, Author ; Patrick Haentjens, Author ; Lorena San Miguel , Author ; Bertien Buyse, Author ; Karolien Benoit, Author ; Stephan Devriese , Author ; Serge Stroobandt, Author ; Jeannine Gailly, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - XIV, 148 p. : ill. ; A4. - (KCE Reports B. Health Technology Assessment (HTA); 156B) .
ISSN : D/2011/10.273/24 : € 0,00
Etude n° 2009-14 HTA Oxygen Therapy
Languages : English (eng) French (fre)
Descriptors: Indexation
2009-14 ; Belgium ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Cystic Fibrosis ; Heart Failure ; Lung Diseases, Interstitial ; Meta-Analysis [Publication Type] ; Oxygen Inhalation Therapy ; Palliative Care ; Pulmonary Disease, Chronic Obstructive ; R156 ; Technology Assessment, Biomedical
Classification
WF 145 Respiratory System - - TherapeuticsContents note: INTRODUCTION 5 -- CHAPTER 1 DESCRIPTION OF THE BELGIAN CONTEXT 6 -- 1 INTRODUCTION 6 -- 2 METHODOLOGY 7 -- 2.1 BELGIAN PRESCRIPTION AND REIMBURSEMENT SYSTEMS 7 -- 2.1.1 Study of the two Belgian prescription systems 7 -- 2.1.2 Number of reimbursements and costs 8 -- 2.2 OXYGEN THERAPY EQUIPMENTS 8 -- 3 RESULTS 9 -- 3.1 PRESCRIPTION AND REIMBURSEMENT SYSTEMS 9 -- 3.1.1 The INAMI/RIZIV-hospital convention system 9 -- 3.1.2 Study of the RIZIV/INAMI agreement with the pharmacists 19 -- 3.1.3 Study of the main differences between both prescription channels 26 -- 3.2 OXYGEN THERAPY EQUIPMENTS 28 -- 3.2.1 Devices used in Belgium 28 -- 3.2.2 Quality control 29 -- CHAPTER 2 CLINICAL LITERATURE REVIEW 38 -- 1 INTRODUCTION 38 -- 2 METHODS 38 -- 2.1 LITERATURE SEARCH STRATEGY 38 -- 2.2 SELECTION CRITERIA 38 -- 2.3 SELECTION PROCEDURE 39 -- 2.4 CRITICAL APPRAISAL 39 -- 2.5 DATA EXTRACTION AND POOLING 40 -- 3 RESULTS 41 -- 3.1 RESEARCH AND SELECTION 41 -- 3.2 RESULTS BY INDICATION 42 -- 3.2.1 COPD 43 -- 3.2.2 Diseases requiring palliative care 57 -- 3.2.3 Heart failure 65 -- 3.2.4 Cystic fibrosis 81 -- 3.2.5 Interstitial lung disease 85 -- CHAPTER 3 ECONOMIC LITERATURE REVIEW 97 -- 1 INTRODUCTION 97 -- 2 METHODS 97 -- 2.1 LITERATURE SEARCH STRATEGY 97 -- 2.2 SELECTION PROCEDURE AND CRITERIA 97 -- 2.3 ECONOMIC EVALUATION SELECTION CRITERIA 98 -- 3 RESULTS 99 -- 3.1 STUDY DESIGN 101 -- 3.2 TYPE OF COST STUDY 101 -- 3.3 TIME FRAME OF STUDY 101 -- 3.4 PERSPECTIVE 102 -- 3.5 POPULATION 102 -- 3.6 COMPARATOR 104 -- 3.6.1 Studies comparing different interventions 104 -- 3.6.2 Studies comparing processes 104 -- 3.7 COSTS AND OUTCOMES 105 -- 3.7.1 Studies Comparing interventions 105 -- 3.7.2 Studies Comparing processes 109 -- 3.8 OTHER RELEVANT STUDIES 115 -- 3.9 MODELLING 116 -- 3.10 UNCERTAINTY ANALYSIS 117 -- 4 DISCUSSION AND CONCLUSIONS 118 -- CHAPTER 4 HEALTH ECONOMIC EVALUATION 120 -- 1 INTRODUCTION & OBJECTIVES 120 -- 2 METHODS 120 -- 2.1 MODEL 120 -- 2.2 PERSPECTIVE 121 -- 2.3 TRANSITION PROBABILITIES 121 -- 2.4 HEALTH RELATED QUALITY OF LIFE 122 -- 2.5 COSTS & RESOURCE USE 122 -- 2.5.1 Data source 122 -- 2.5.2 Analysis sample 122 -- 2.5.3 Descriptive statistics of the analysis sample 123 -- 2.5.4 Cost calculations 124 -- 2.6 ICER 125 -- 2.7 SENSITIVITY ANALYSIS 125 -- 2.8 SCENARIO ANALYSIS 125 -- 3 RESULTS 126 -- 3.1 BASE CASE SCENARIO 126 -- 3.2 ALTERNATIVE SCENARIO 126 -- 4 DISCUSSION AND CONCLUSION 128 -- CHAPTER 5 INTERNATIONAL COMPARISON 129 -- 1 INTRODUCTION 129 -- 2 METHODOLOGY 129 -- 3 RESULTS 130 -- 3.1 REGULATION OF PRESCRIPTION 130 -- 3.2 CHANNELS OF PROVISION AND HOME SUPERVISION 130 -- 3.3 REIMBURSEMENT SYSTEM 131 -- 4 DISCUSSION & CONCLUSION 135 -- CHAPTER 6 FINAL CONCLUSIONS AND LIMITATIONS 136 -- 1 CLINICAL EFFICACY 136 -- 1.1.1 COPD 136 -- 1.1.2 Patients necessitating palliative care (PC) 137 -- 1.1.3 Heart failure (HF) 137 -- 1.1.4 Cystic fibrosis (CF) 137 -- 1.1.5 Interstitial lung disease (ILD) 138 -- 2 COMPARISON OF AVAILABLE PRODUCTS 139 -- 3 COST IN BELGIUM 140 -- 4 ORGANISATION MODELS 141 -- REFERENCES 142 Link for e-copy: http://doi.org/10.57598/R156B Format of e-copy: PDF (3,695 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2575 Copies(0)
Status No copy Zuurstoftherapie thuis / Alain Van Meerhaeghe / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
Zuurstoftherapie thuis [printed text] / Alain Van Meerhaeghe, Author ; Lieven Annemans, Author ; Patrick Haentjens, Author ; Lorena San Miguel , Author ; Bertien Buyse, Author ; Karolien Benoit, Author ; Stephan Devriese , Author ; Serge Stroobandt, Author ; Jeannine Gailly, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - XIV, 148 p. : ill. ; A4. - (KCE Reports A. Health Technology Assessment (HTA); 156A) .
ISSN : D/2011/10.273/23 : € 0,00
Studie n° 2009-14 HTA Oxygen Therapy
Languages : English (eng) Dutch (nla)
Descriptors: Indexation
2009-14 ; Belgium ; Cost-Benefit Analysis ; Costs and Cost Analysis ; Cystic Fibrosis ; Heart Failure ; Lung Diseases, Interstitial ; Meta-Analysis [Publication Type] ; Oxygen Inhalation Therapy ; Palliative Care ; Pulmonary Disease, Chronic Obstructive ; R156 ; Technology Assessment, Biomedical
Classification
WF 145 Respiratory System - - TherapeuticsAbstract: Personen met chronisch longlijden kunnen soms thuis behoefte hebben aan extra zuurstoftoediening. In België kan zulke zuurstoftherapie zonder enige beperking door elke arts worden voorgeschreven, en de laatste jaren ziet men een grote stijging van de uitgaven. Bij de organisatie van de therapie zijn verschillende beleidsinstanties en privé- en beroepsorganisaties betrokken, waardoor een globale visie ontbreekt. Het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) pleit voor het herbekijken van de prijzen en voor de minst dure methodes om de zuurstof toe te dienen, vermits ze toch een gelijkwaardig medisch effect hebben. Verder wordt de langdurige therapie best voorbehouden voor patiënten bij wie het wetenschappelijk bewezen is dat ze er baat bij hebben: mensen met zeer ernstige ademnood door COPD, mucoviscidose, hartfalen en bepaalde longziekten. Contents note: INTRODUCTION 5 -- CHAPTER 1 DESCRIPTION OF THE BELGIAN CONTEXT 6 -- 1 INTRODUCTION 6 -- 2 METHODOLOGY 7 -- 2.1 BELGIAN PRESCRIPTION AND REIMBURSEMENT SYSTEMS 7 -- 2.1.1 Study of the two Belgian prescription systems 7 -- 2.1.2 Number of reimbursements and costs 8 -- 2.2 OXYGEN THERAPY EQUIPMENTS 8 -- 3 RESULTS 9 -- 3.1 PRESCRIPTION AND REIMBURSEMENT SYSTEMS 9 -- 3.1.1 The INAMI/RIZIV-hospital convention system 9 -- 3.1.2 Study of the RIZIV/INAMI agreement with the pharmacists 19 -- 3.1.3 Study of the main differences between both prescription channels 26 -- 3.2 OXYGEN THERAPY EQUIPMENTS 28 -- 3.2.1 Devices used in Belgium 28 -- 3.2.2 Quality control 29 -- CHAPTER 2 CLINICAL LITERATURE REVIEW 38 -- 1 INTRODUCTION 38 -- 2 METHODS 38 -- 2.1 LITERATURE SEARCH STRATEGY 38 -- 2.2 SELECTION CRITERIA 38 -- 2.3 SELECTION PROCEDURE 39 -- 2.4 CRITICAL APPRAISAL 39 -- 2.5 DATA EXTRACTION AND POOLING 40 -- 3 RESULTS 41 -- 3.1 RESEARCH AND SELECTION 41 -- 3.2 RESULTS BY INDICATION 42 -- 3.2.1 COPD 43 -- 3.2.2 Diseases requiring palliative care 57 -- 3.2.3 Heart failure 65 -- 3.2.4 Cystic fibrosis 81 -- 3.2.5 Interstitial lung disease 85 -- CHAPTER 3 ECONOMIC LITERATURE REVIEW 97 -- 1 INTRODUCTION 97 -- 2 METHODS 97 -- 2.1 LITERATURE SEARCH STRATEGY 97 -- 2.2 SELECTION PROCEDURE AND CRITERIA 97 -- 2.3 ECONOMIC EVALUATION SELECTION CRITERIA 98 -- 3 RESULTS 99 -- 3.1 STUDY DESIGN 101 -- 3.2 TYPE OF COST STUDY 101 -- 3.3 TIME FRAME OF STUDY 101 -- 3.4 PERSPECTIVE 102 -- 3.5 POPULATION 102 -- 3.6 COMPARATOR 104 -- 3.6.1 Studies comparing different interventions 104 -- 3.6.2 Studies comparing processes 104 -- 3.7 COSTS AND OUTCOMES 105 -- 3.7.1 Studies Comparing interventions 105 -- 3.7.2 Studies Comparing processes 109 -- 3.8 OTHER RELEVANT STUDIES 115 -- 3.9 MODELLING 116 -- 3.10 UNCERTAINTY ANALYSIS 117 -- 4 DISCUSSION AND CONCLUSIONS 118 -- CHAPTER 4 HEALTH ECONOMIC EVALUATION 120 -- 1 INTRODUCTION & OBJECTIVES 120 -- 2 METHODS 120 -- 2.1 MODEL 120 -- 2.2 PERSPECTIVE 121 -- 2.3 TRANSITION PROBABILITIES 121 -- 2.4 HEALTH RELATED QUALITY OF LIFE 122 -- 2.5 COSTS & RESOURCE USE 122 -- 2.5.1 Data source 122 -- 2.5.2 Analysis sample 122 -- 2.5.3 Descriptive statistics of the analysis sample 123 -- 2.5.4 Cost calculations 124 -- 2.6 ICER 125 -- 2.7 SENSITIVITY ANALYSIS 125 -- 2.8 SCENARIO ANALYSIS 125 -- 3 RESULTS 126 -- 3.1 BASE CASE SCENARIO 126 -- 3.2 ALTERNATIVE SCENARIO 126 -- 4 DISCUSSION AND CONCLUSION 128 -- CHAPTER 5 INTERNATIONAL COMPARISON 129 -- 1 INTRODUCTION 129 -- 2 METHODOLOGY 129 -- 3 RESULTS 130 -- 3.1 REGULATION OF PRESCRIPTION 130 -- 3.2 CHANNELS OF PROVISION AND HOME SUPERVISION 130 -- 3.3 REIMBURSEMENT SYSTEM 131 -- 4 DISCUSSION & CONCLUSION 135 -- CHAPTER 6 FINAL CONCLUSIONS AND LIMITATIONS 136 -- 1 CLINICAL EFFICACY 136 -- 1.1.1 COPD 136 -- 1.1.2 Patients necessitating palliative care (PC) 137 -- 1.1.3 Heart failure (HF) 137 -- 1.1.4 Cystic fibrosis (CF) 137 -- 1.1.5 Interstitial lung disease (ILD) 138 -- 2 COMPARISON OF AVAILABLE PRODUCTS 139 -- 3 COST IN BELGIUM 140 -- 4 ORGANISATION MODELS 141 -- REFERENCES 142 Link for e-copy: https://doi.org/10.57598/R156A Format of e-copy: PDF (3,7 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2576 Hold
Place a hold on this item
Copies(1)
Barcode Call number Media type Location Section Status 10273-02316 WF 145 / VAN Report KCE Library (10.124) Available